BeiCell Therapeutics is a revolutionary cell therapy company stemming from Prof. Hongkui Deng's lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 海淀区永嘉北路4号院一号楼 中关村科学城星谷, Beijing,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- CiPS, Chemically induced pluripotent stem cell, Cell therapy, Off-the-Shelf, T Cells, CAR-T, Stem Cells, Cancer, Oncology, Biotechnology, Gene Editing, Regenrative Medicine, Allogeneic Cell Theray.
- HQ
- Beijing
Beicell Therapeutics Questions
Beicell Therapeutics's website is http://www.beicelltherapeutics.com/en
Beicell Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/beicell-therapeutics
Beicell Therapeutics has
2 employees.
View email and phone details for 2
employees at Beicell Therapeutics.
Beicell Therapeutics's industry is
Biotechnology Research
Beicell Therapeutics's top competitors are
Beam Therapeutics,
Plant-Ditech,
Bluerock Therapeutics,
Marsway Human Resource Consulting Co., Ltd,
Shanton Pharma,
Aspect Biosystems,
Targenomix Gmbh,
Oncusp Therapeutics,
Biotrack Capital,
Exoneuglia Biotechnology (Suzhou) Co., Ltd..
Beicell Therapeutics's categories are Biotechnology Research
Beicell Therapeutics's founding year is 2022
